INDIANAPOLIS and CAMBRIDGE, Mass., June 29, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Sigilon Therapeutics, Inc. (Nasdaq:SGTX) today announced a definitive agreement for Lilly to acquire Sigilon, a biopharmaceutical company that seeks to develop functional cures for patients with a broad range of acute and chronic diseases.
Read more at prnewswire.comLilly to Acquire Sigilon Therapeutics
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here